OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J. Krause, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. 597-610
Open Access | Times Cited: 53
Karim Fizazi, Ken Herrmann, Bernd J. Krause, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. 597-610
Open Access | Times Cited: 53
Showing 1-25 of 53 citing articles:
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 99-107
Closed Access | Times Cited: 81
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 99-107
Closed Access | Times Cited: 81
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J. Morris, Daniel Castellano, Ken Herrmann, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1227-1239
Closed Access | Times Cited: 31
Michael J. Morris, Daniel Castellano, Ken Herrmann, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1227-1239
Closed Access | Times Cited: 31
New Insights into Antioxidant Peptides: An Overview of Efficient Screening, Evaluation Models, Molecular Mechanisms, and Applications
Yuhao Zhang, Yun Li, Zhengze Quan, et al.
Antioxidants (2024) Vol. 13, Iss. 2, pp. 203-203
Open Access | Times Cited: 20
Yuhao Zhang, Yun Li, Zhengze Quan, et al.
Antioxidants (2024) Vol. 13, Iss. 2, pp. 203-203
Open Access | Times Cited: 20
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617
Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, et al.
Theranostics (2024) Vol. 14, Iss. 5, pp. 1829-1840
Open Access | Times Cited: 16
Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, et al.
Theranostics (2024) Vol. 14, Iss. 5, pp. 1829-1840
Open Access | Times Cited: 16
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N., Andrew J. Armstrong, Bernd J. Krause, et al.
European Urology (2024) Vol. 85, Iss. 4, pp. 382-391
Open Access | Times Cited: 13
Kim N., Andrew J. Armstrong, Bernd J. Krause, et al.
European Urology (2024) Vol. 85, Iss. 4, pp. 382-391
Open Access | Times Cited: 13
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Tivya Kulasegaran, Niara Oliveira
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 7, pp. 914-931
Open Access | Times Cited: 12
Tivya Kulasegaran, Niara Oliveira
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 7, pp. 914-931
Open Access | Times Cited: 12
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
Lena M. Unterrainer, Jérémie Calais, Neil H. Bander
Annual Review of Medicine (2024) Vol. 75, Iss. 1, pp. 49-66
Open Access | Times Cited: 8
Lena M. Unterrainer, Jérémie Calais, Neil H. Bander
Annual Review of Medicine (2024) Vol. 75, Iss. 1, pp. 49-66
Open Access | Times Cited: 8
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)
Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, et al.
Radiology (2024) Vol. 312, Iss. 2
Closed Access | Times Cited: 8
Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, et al.
Radiology (2024) Vol. 312, Iss. 2
Closed Access | Times Cited: 8
Current clinical application of lutetium‑177 in solid tumors (Review)
Tingting Niu, Fan Mi, Binwei Lin, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access | Times Cited: 6
Tingting Niu, Fan Mi, Binwei Lin, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access | Times Cited: 6
PSMA-targeted therapy for non-prostate cancers
Jarey H. Wang, Ana P. Kiess
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Jarey H. Wang, Ana P. Kiess
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Radioactivity levels in the saliva of patients undergoing targeted radioligand therapy with [177Lu]Lu-PSMA-I&T and [177Lu]Lu-DOTA-TOC
Christian Schedeit, Nasir Gözlügöl, Radi Saiyed Alsheikh, et al.
Clinical Oral Investigations (2025) Vol. 29, Iss. 5
Open Access
Christian Schedeit, Nasir Gözlügöl, Radi Saiyed Alsheikh, et al.
Clinical Oral Investigations (2025) Vol. 29, Iss. 5
Open Access
PSMA Radioligand Therapy in Prostate Cancer
Ludmila Santiago Almeida, Elba Etchebehere, Irene García Megías, et al.
Clinical Nuclear Medicine (2023) Vol. 49, Iss. 1, pp. 45-55
Closed Access | Times Cited: 12
Ludmila Santiago Almeida, Elba Etchebehere, Irene García Megías, et al.
Clinical Nuclear Medicine (2023) Vol. 49, Iss. 1, pp. 45-55
Closed Access | Times Cited: 12
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
Kim N., Steven Yip, Glenn Bauman, et al.
Current Oncology (2024) Vol. 31, Iss. 3, pp. 1400-1415
Open Access | Times Cited: 4
Kim N., Steven Yip, Glenn Bauman, et al.
Current Oncology (2024) Vol. 31, Iss. 3, pp. 1400-1415
Open Access | Times Cited: 4
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy
Kerry Jewell, Michael S. Hofman, Jeremy S. L. Ong, et al.
Radiology (2024) Vol. 311, Iss. 1
Closed Access | Times Cited: 4
Kerry Jewell, Michael S. Hofman, Jeremy S. L. Ong, et al.
Radiology (2024) Vol. 311, Iss. 1
Closed Access | Times Cited: 4
177Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
Andreas Poschenrieder, Jasminka Taleska, Leonhard Schaetz
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 9, pp. 1340-1342
Open Access | Times Cited: 4
Andreas Poschenrieder, Jasminka Taleska, Leonhard Schaetz
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 9, pp. 1340-1342
Open Access | Times Cited: 4
Innovation thérapeutique et enjeux capacitaires en médecine nucléaire : la situation de la RIV en Occitanie
Romain Guignard, B. Chambert, H. Collet, et al.
Médecine Nucléaire (2025)
Closed Access
Romain Guignard, B. Chambert, H. Collet, et al.
Médecine Nucléaire (2025)
Closed Access
Endogenous peptide CBDP1 inhibits clear cell renal cell carcinoma progression by targeting USP5/YTHDF2/TRPM5 axis
Yang Zhang, Wei Zhu, Ruijie Tao, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Yang Zhang, Wei Zhu, Ruijie Tao, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
André P. Fay, Karim Fizazi, Nobuaki Matsubara, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. 481-490
Closed Access
André P. Fay, Karim Fizazi, Nobuaki Matsubara, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. 481-490
Closed Access
Pre- or post-chemotherapy: effect on PSMA uptake
Surekha Yadav, Abuzar Moradi Tuchayi, Moein Moradpour, et al.
EJNMMI Research (2025) Vol. 15, Iss. 1
Open Access
Surekha Yadav, Abuzar Moradi Tuchayi, Moein Moradpour, et al.
EJNMMI Research (2025) Vol. 15, Iss. 1
Open Access
Polymer composite microspheres loading 177 Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer
Xiao Liu, Yuhao Li, Ruiman Geng, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 9
Xiao Liu, Yuhao Li, Ruiman Geng, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 9
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
Ronan Flippot, Tuğçe Telli, Maud Velev, et al.
European Urology Oncology (2024) Vol. 7, Iss. 5, pp. 1132-1140
Open Access | Times Cited: 3
Ronan Flippot, Tuğçe Telli, Maud Velev, et al.
European Urology Oncology (2024) Vol. 7, Iss. 5, pp. 1132-1140
Open Access | Times Cited: 3
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
Maurizio Capuozzo, Mariachiara Santorsola, Monica Ianniello, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 87-87
Open Access | Times Cited: 3
Maurizio Capuozzo, Mariachiara Santorsola, Monica Ianniello, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 87-87
Open Access | Times Cited: 3
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
Ken Herrmann, Andrei Gafita, Johann S. de Bono, et al.
EClinicalMedicine (2024) Vol. 77, pp. 102862-102862
Open Access | Times Cited: 3
Ken Herrmann, Andrei Gafita, Johann S. de Bono, et al.
EClinicalMedicine (2024) Vol. 77, pp. 102862-102862
Open Access | Times Cited: 3
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
Amar U. Kishan, Shankar Siva, Michael S. Hofman, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 4, pp. 502-509
Open Access | Times Cited: 2
Amar U. Kishan, Shankar Siva, Michael S. Hofman, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 4, pp. 502-509
Open Access | Times Cited: 2
Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection
Surekha Yadav, Sarasa T. Kim, Abuzar Moradi Tuchayi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Surekha Yadav, Sarasa T. Kim, Abuzar Moradi Tuchayi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
